The medical landscape for chronic rhinosinusitis is rapidly advancing, with new treatments offering hope for improved quality of life for patients. As pharmaceutical companies race to develop ...
Priority Review approval extends dupilumab into AFRS with prior surgery, expanding sino-nasal indications beyond CRSwNP and representing the ninth FDA-approved indication across type 2 inflammatory ...
The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis.
Phase 3 LIBERTY-AIMS results showed dupilumab reduced nasal polyp size and sinus symptoms in adults and children with allergic fungal rhinosinusitis.
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (OPTN) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...
Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery ...
You may be reading this because you or someone you care about has nasal cavity or sinus cancer. Learning more can help you get ready to talk with your healthcare provider and understand the next steps ...
Please provide your email address to receive an email when new articles are posted on . Acute disease exacerbations fell to 66% with treatment — a 56% reduction — compared with placebo. Congestion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results